ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 44 citations in OpenAlex.
- Feline Mammary Carcinoma as a Comparative Model of Human Breast Cancer: An Integrative Review.Cancers · 2026Article
- Tissue Proteomics of Feline Mammary Carcinoma: Differences in Protein Profiles Among Histological Grades Using Liquid Chromatography-Tandem Mass Spectrometry.Veterinary and comparative oncology · 2026Article
- Serum programmed death ligand 2 is elevated in cats with mammary carcinoma.Scientific reports · 2026Article
- Advancing In Vitro Tools for Oncologic Research in Cats and Dogs.Veterinary sciences · 2025Review
- Feline Mammary Tumors: A Comprehensive Review of Histological Classification Schemes, Grading Systems, and Prognostic Factors.Veterinary sciences · 2025Review
- Prognostic Insights in Feline Mammary Carcinomas: Clinicopathological Factors and the Proposal of a New Staging System.Animals : an open access journal from MDPI · 2025Article
- Phosphoproteomic profiling of feline mammary carcinoma: Insights into tumor grading and potential therapeutic targets.PloS one · 2025Article
- Analysis of serum peptidome profiles of non-metastatic and metastatic feline mammary carcinoma using liquid chromatography-tandem mass spectrometry.BMC veterinary research · 2024Article
- Adipocyte-Derived Adipokines and Other Obesity-Associated Molecules in Feline Mammary Cancer.Biomedicines · 2023Review
- Prevention and Therapy of Metastatic HER-2Biomedicines · 2022Article
- Transcription profiling of feline mammary carcinomas and derived cell lines reveals biomarkers and drug targets associated with metabolic and cell cycle pathways.Scientific reports · 2022Article
- Feline Oncogenomics: What Do We Know about the Genetics of Cancer in Domestic Cats?Veterinary sciences · 2022Review
- Article
- VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes.Cancers · 2021Article
- Establishment and Characterization of Feline Mammary Tumor Patient-Derived Xenograft Model.Animals : an open access journal from MDPI · 2021Article
- Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma.Veterinary sciences · 2021Review
- Article
- Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma.Pharmaceutics · 2021Article
- Histone Deacetylase Inhibitors and Microtubule Inhibitors Induce Apoptosis in Feline Luminal Mammary Carcinoma Cells.Animals : an open access journal from MDPI · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considering that scarce data are available on disease progression of feline mammary carcinoma (FMC), this study aimed to analyze the clinical, pathological, and immunophenotypic features collected from 61 queens with FMC and to compare the concordance ratios of the expression levels of five molecular markers (ER, PR, fHER2, CK5/6, and Ki-67) between primary tumors (PT) and metastatic lesions. The results showed that cats with luminal A mammary carcinomas (MC) had higher overall survival (924.6 days, p = 0.001) and longer disease-free period (385.4 days, p = 0.005) compared to the ones with other MC subtypes. In fact, queens with triple negative/basal-like MC showed the lowest survival (mean 156.2 days) and the shortest disease-free survival (mean 28 days) among the molecular subtypes of MC. The lung was the organ most frequently affected by metastases, and animals with lung and/or pleural metastases were more likely to display metastases at three or more locations (p = 0.039). A large heterogeneity in protein expression levels was found between PT and paired metastases, with both estrogen and progesterone receptors more likely to be downregulated in metastases. Paired metastases frequently had higher Ki-67 index than PT, whereas fHER2 overexpression was seen in 46 samples (30 %) and CK5/6 expression was found in 50.7 % of metastases (36/71). Results also revealed that disease progression leads to a high percentage of triple negative/basal-like metastases (9/23; 39.1 %) associated with the absence of luminal A subtype in distant metastases (0/23). This study highlights the prognostic importance of immunophenotyping of MC in cats, although the modified protein expression identified in metastases contributes to justify why possible targeted therapies may fail in some animals with metastatic disease. Altogether, the results obtained also demonstrate that FMC can be used as a model to study human breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.